Murphy G S, Bodhidatta L, Echeverria P, Tansuphaswadikul S, Hoge C W, Imlarp S, Tamura K
Naval Medical Research Unit Number 2, Jakarta, Indonesia.
Ann Intern Med. 1993 Apr 15;118(8):582-6. doi: 10.7326/0003-4819-118-8-199304150-00002.
To compare the safety and efficacy of loperamide plus ciprofloxacin with those of ciprofloxacin alone in the treatment of bacillary dysentery.
Double-blind, placebo-controlled, randomized clinical trial.
Hospital in Thailand.
Eighty-eight adults with dysentery seeking medical care between November 1990 and February 1992. Patients who had received prior antibiotics or antimotility drugs were excluded.
All 88 patients with dysentery were treated with ciprofloxacin, 500 mg twice daily for 3 days. Forty-two of these patients were randomly assigned to receive loperamide, a 4-mg initial dose followed by 2 mg after every loose stool (as many as eight caplets [16 mg] daily), and 46 were randomly assigned to receive placebo.
Stools were collected daily until resolution of diarrhea and again after 10 days. The time to passage of the last unformed stool, number of unformed stools, and symptoms were recorded after treatment.
Shigella or enteroinvasive Escherichia coli (53%), Vibrio parahaemolyticus (16%), and Salmonella (7%) were the most common bacterial enteric pathogens identified in 88 patients with dysentery. In patients infected with Shigella or enteroinvasive E. coli, the median duration of diarrhea was 19 hours (25th to 75th percentiles, 6 to 42 hours) for those receiving loperamide plus ciprofloxacin compared with 42 hours (21 to 46 hours) for those receiving ciprofloxacin alone (P = 0.028). The median number of diarrheal stools for those receiving ciprofloxacin and loperamide was 2.0 (1 to 5 stools) compared with 6.5 (2 to 9 stools) for those receiving ciprofloxacin alone (P = 0.016). None of the participants had a temperature greater than 38 degrees C after 24 hours of treatment. None of the patients was infected with the same bacterial enteric pathogen more than 1 day after receiving treatment.
Loperamide decreases the number of unformed stools and shortens the duration of diarrhea in dysentery caused by Shigella in adults treated with ciprofloxacin.
比较洛哌丁胺加环丙沙星与单用环丙沙星治疗细菌性痢疾的安全性和疗效。
双盲、安慰剂对照、随机临床试验。
泰国的一家医院。
1990年11月至1992年2月期间88名因痢疾就医的成年人。排除先前接受过抗生素或止泻药治疗的患者。
88例痢疾患者均接受环丙沙星治疗,每日两次,每次500mg,共3天。其中42例患者被随机分配接受洛哌丁胺治疗,初始剂量为4mg,之后每腹泻一次服用2mg(每日最多8粒[16mg]),46例患者被随机分配接受安慰剂治疗。
每天收集粪便,直至腹泻症状消失,10天后再次收集。记录治疗后最后一次不成形粪便排出时间、不成形粪便数量及症状。
88例痢疾患者中,最常见的肠道病原菌为志贺菌或侵袭性大肠杆菌(53%)、副溶血性弧菌(16%)和沙门菌(7%)。在感染志贺菌或侵袭性大肠杆菌的患者中,接受洛哌丁胺加环丙沙星治疗的患者腹泻中位持续时间为19小时(第25至75百分位数为6至42小时),而单用环丙沙星治疗的患者为42小时(21至46小时)(P = 0.028)。接受环丙沙星和洛哌丁胺治疗的患者腹泻粪便中位数量为2.0次(1至5次),而单用环丙沙星治疗的患者为6.5次(2至9次)(P = 0.016)。治疗24小时后,所有参与者体温均未超过38摄氏度。治疗后,无患者在1天以上感染相同的肠道病原菌。
在接受环丙沙星治疗的成年志贺菌引起的痢疾患者中,洛哌丁胺可减少不成形粪便数量,缩短腹泻持续时间。